Terumo (TRUMY)
(Delayed Data from OTC)
$18.70 USD
+0.04 (0.21%)
Updated Sep 18, 2024 03:53 PM ET
2-Buy of 5 2
B Value C Growth A Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TRUMY 18.70 +0.04(0.21%)
Will TRUMY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TRUMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRUMY
What Makes Terumo (TRUMY) a New Buy Stock
Terumo (TRUMY) Unit Reveals WEB 17 Device Effective in Aneurysms
TRUMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Terumo (TRUMY) Unit's SOFAST Study Shows Positive Results
Terumo (TRUMY) Moves to Strong Buy: Rationale Behind the Upgrade
Best Momentum Stocks to Buy for March 28th
Other News for TRUMY
MicroVention Rebrands to Terumo Neuro ? Reflects Expanded Focus and Strategic Growth
Terumo Corporation (TRUMF) Q1 2025 Earnings Call Transcript
Terumo Establishes Corporate Venture Capital "Terumo Ventures"
Terumo Gaining Share In Growth Markets, But Consistency Still A Question
MicroVention Announces Release of CLinical EValuation of WEB? 17 Device in Intracranial Aneurysms (CLEVER): One Year Effectiveness Results for Ruptured and Unruptured Aneurysms